Edgewise Therapeutics Inc... (EWTX)
| Bid | 16.72 |
| Market Cap | 2.17B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -137.85M |
| EPS (ttm) | -1.45 |
| PE Ratio (ttm) | -15.71 |
| Forward PE | -14.98 |
| Analyst | Buy |
| Ask | 24.33 |
| Volume | 698,008 |
| Avg. Volume (20D) | 1,135,815 |
| Open | 23.07 |
| Previous Close | 23.37 |
| Day's Range | 22.72 - 23.88 |
| 52-Week Range | 14.90 - 38.12 |
| Beta | 0.23 |
About EWTX
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that t...
Analyst Forecast
According to 8 analyst ratings, the average rating for EWTX stock is "Buy." The 12-month stock price forecast is $50, which is an increase of 119.54% from the latest price.
Stock Forecasts
2 weeks ago · seekingalpha.com
Edgewise Therapeutics: More Expensive Now, But Much More DeriskedEdgewise Therapeutics' stock surged after strong midstage data from its Becker Muscular Dystrophy program, with the lead molecule sevasemten showing promising results. The GRAND CANYON trial, targetin...
2 months ago · seekingalpha.com
Edgewise: Remains A Buy After Latest Becker Muscular Dystrophy DataCompany achieved positive phase 2 CANYON study results for sevasemten in Becker Muscular Dystrophy, boosting long-term investment potential. Key catalysts include FDA and EMA meetings, GRAND CANYON st...